Aisling Capital Management LP Aeglea Bio Therapeutics, Inc. Transaction History

Aisling Capital Management LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 10, 2020	BUY	$4.01 - $11.04 $1.6 Million - $4.42 Million	400,000 Added 30.98%	1,691,151 $15.6 Million
Q2 2019 Aug 08, 2019	BUY	$6.1 - $8.78 $428,464 - $616,707	70,240 Added 5.75%	1,291,151 $8.84 Million
Q1 2019 May 20, 2019	BUY	$7.6 - $9.4 $2.68 Million - $3.31 Million	352,290 Added 40.56%	1,220,911 $9.83 Million
Q4 2018 Feb 08, 2019	BUY	$6.51 - $10.19 $5.65 Million - $8.85 Million	868,621 New	868,621 $6.51 Million

241K

Ticker AGLE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,172,500
Market Cap $1.69B
Description
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy f...

Get notified when there are updates to the investment portfolio of Aisling Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Aisling Capital Management LP with notifications on news.